Different findings in Tc-99m MDP bone scintigraphy of patients with sickle cell disease: report of three cases

Abstract

In light of the findings in these cases, bone scintigraphy is a reliable imaging method in detecting both osseous and extraosseous abnormalities of sickle cell disease and may be used initially.

Altered Biodistribution of Radiopharmaceuticals Used in Bone Scintigraphy

“…8 and 9). Splenic uptake may be observed in autoinfarction associated with sickle cell anemia ("autoinfarction") [132][133][134] (Fig. 10), but it can be due to other causes, such as lymphoma, as well.…”

Extraosseous myocardial uptake incidentally detected during bone scan: report of three cases and a systematic literature review of extraosseous uptake

“…Extraosseous uptakes of 99mTc-labelled phosphates involving other organs are reported in patients with leukemia [41][42][43][44], parathyroid carcinoma [45], parathyroid adenoma [46], renal failure [38,47,48], lymphomas [49][50][51], multiple myeloma [52,53], Waldenstrom macroglobulinemia [12,54], hematological disorders [55][56][57][58][59][60], tumors [61][62][63][64][65][66][67][68][69], calcinosis [70,71] and vasculitis [72].…”

Nano‐sized Carrier Systems as New Materials for Nuclear Medicine

“…Hydroxybisphosphonates and their metal complexes are very quickly and strongly accumulated in bones after administration [75] and inhibit bone resorption, which is exploited in paliative treatment of bone metastases [75][76][77], therapy of osteoporosis [75,77] and of Paget disease [75]. Radiometal complexes of bisphosphonates, especially methylenediphosphonate complex with 99m Tc, are widely used in bone scintigraphy [78][79][80], since bisphosphonates accumulate more in places of bone with high remodelling rate where hydroxyapatite is more exposed to blood, i.e. in bone metastases and broken/damaged areas [78][79][80].…”

“…Radiometal complexes of bisphosphonates, especially methylenediphosphonate complex with 99m Tc, are widely used in bone scintigraphy [78][79][80], since bisphosphonates accumulate more in places of bone with high remodelling rate where hydroxyapatite is more exposed to blood, i.e. in bone metastases and broken/damaged areas [78][79][80]. This is why hydroxybisphosphonate moieties were also proposed for targeting of polymer carriers [81,82].…”

“…For both radioimaging purposes and radiotherapy, physical half-life from severeal hours to few days is optimal, offering both enough time for targeting and sufficiently fast extinction of radioactivity from the organism after the the system fulfills its task. The radionuclides most commonly studied or used in connection with nanomedicines for planar scintigraphy and SPECT are γ-emitters 99m Tc (23,25,79,83,95), m In [T 1/2 = 2.8047 days, 171.3 keV (90%), 245.4 keV (94%)] [96,97] and radionuclides which may be used both for radiotherapy and imaging since they are primarily ß" emitters, but with accompanying γ-emission, i.e. m l [T 1/2 = 8.02 days, 364.5 keV (81.7%) + several minor γ-lines] [54] and 188 Re [T 1/2 = 17.01 h, 155.0 keV (15%)] [98,99].…”